{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:12:03Z","timestamp":1753877523198,"version":"3.41.2"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>We evaluated rapid start of integrase-based antiretroviral therapy (ART) during acute HIV-1.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Adult participants initiated co-formulated dolutegravir\/abacavir\/lamivudine within 30 days of acute HIV-1 diagnosis. HLA-B*57-positive participants were excluded by rapid, flow cytometry screening. We evaluated HIV-1 RNA levels, CD4+ T-cell subsets, and change in replication competent HIV-1.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Forty adults screened with 3 excluded due to positive HLA-B*57:01 or hepatitis B surface antigen results. All 37 participants starting study treatment suppressed to &amp;lt;200 copies\/mL by week 24 (median of 4 weeks, interquartile range 3.4\u20135.1); 86% and 95% were &amp;lt;50\u2005copies\/mL at weeks 48 and 96, respectively. We observed a median 2.4-fold decline in frequency of resting CD4+ T-cell infection in a subset of participants providing 96 week samples. ART in acute HIV-1 resulted in CD4+ T-cell memory subpopulations similar to people without HIV-1 and preserved CD4+ and CD8+ T-cell frequencies compared to people starting ART in chronic HIV. Thirty-four participants required rapid HLA-B*57 testing at screening; 97% resulted \u226424\u2005hours, and 71% started ART \u226424\u2005hours.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Integrase-based ART during acute HIV-1 resulted in brisk viral suppression, preservation of CD4+ T-cell subsets, and decline in resting CD4+ T-cell infection.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofaf247","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T03:45:38Z","timestamp":1745552738000},"source":"Crossref","is-referenced-by-count":0,"title":["Dolutegravir\/Abacavir\/Lamivudine in Acute HIV-1 Results in Rapid Suppression and Restoration of CD4 T-cell Subsets Without Accelerated Decay of Latent HIV-1"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3620-3059","authenticated-orcid":false,"given":"Cynthia L","family":"Gay","sequence":"first","affiliation":[{"name":"Department of Medicine, University of North Carolina at Chapel Hill (UNC) School of Medicine , Chapel Hill, North Carolina ,","place":["USA"]},{"name":"UNC Chapel Hill HIV Cure Center , University of North Carolina at Chapel Hilll, Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5093-378X","authenticated-orcid":false,"given":"Jessica","family":"Keys","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of North Carolina at Chapel Hill (UNC) School of Medicine , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JoAnn D","family":"Kuruc","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of North Carolina at Chapel Hill (UNC) School of Medicine , Chapel Hill, North Carolina ,","place":["USA"]},{"name":"UNC Chapel Hill HIV Cure Center , University of North Carolina at Chapel Hilll, Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Sponaugle","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kara S","family":"McGee","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University , Durham, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chelston","family":"Ang","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]},{"name":"UNC NC State Joint Department of Biomedical Engineering , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline E","family":"Baker","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of North Carolina at Chapel Hill (UNC) School of Medicine , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric T","family":"Weimer","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1425-236X","authenticated-orcid":false,"given":"John L","family":"Schmitz","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]},{"name":"Department of Pathology & Laboratory Medicine, The University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancie M","family":"Archin","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of North Carolina at Chapel Hill (UNC) School of Medicine , Chapel Hill, North Carolina ,","place":["USA"]},{"name":"UNC Chapel Hill HIV Cure Center , University of North Carolina at Chapel Hilll, Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehri S","family":"McKellar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University , Durham, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilu","family":"Goonetilleke","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of North Carolina at Chapel Hill (UNC) School of Medicine , Chapel Hill, North Carolina ,","place":["USA"]},{"name":"UNC Chapel Hill HIV Cure Center , University of North Carolina at Chapel Hilll, Chapel Hill, North Carolina ,","place":["USA"]},{"name":"Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5714-0002","authenticated-orcid":false,"given":"David M","family":"Margolis","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of North Carolina at Chapel Hill (UNC) School of Medicine , Chapel Hill, North Carolina ,","place":["USA"]},{"name":"UNC Chapel Hill HIV Cure Center , University of North Carolina at Chapel Hilll, Chapel Hill, North Carolina ,","place":["USA"]},{"name":"Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4938-0644","authenticated-orcid":false,"given":"Joseph J","family":"Eron","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of North Carolina at Chapel Hill (UNC) School of Medicine , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"2025052602120295800_ofaf247-B1","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/QAD.0000000000002124","article-title":"RAPID antiretroviral therapy: high virologic suppression rates with immediate antiretroviral therapy initiation in a vulnerable urban clinic population","volume":"33","author":"Coffey","year":"2019","journal-title":"AIDS"},{"key":"2025052602120295800_ofaf247-B2","doi-asserted-by":"crossref","first-page":"ofz161","DOI":"10.1093\/ofid\/ofz161","article-title":"A care Continuum of immediate ART for newly diagnosed patients and patients presenting later to care at a federally qualified health center in New Orleans","volume":"6","author":"Halperin","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2025052602120295800_ofaf247-B3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/QAD.0000000000001671","article-title":"Benefits and risks of rapid initiation of antiretroviral therapy","volume":"32","author":"Ford","year":"2018","journal-title":"AIDS"},{"key":"2025052602120295800_ofaf247-B4","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1172\/JCI7371","article-title":"HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy","volume":"104","author":"Ortiz","year":"1999","journal-title":"J Clin Invest"},{"key":"2025052602120295800_ofaf247-B5","doi-asserted-by":"crossref","first-page":"e1004543","DOI":"10.1371\/journal.ppat.1004543","article-title":"Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation","volume":"10","author":"Schuetz","year":"2014","journal-title":"PLoS Pathog"},{"key":"2025052602120295800_ofaf247-B6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/QAI.0000000000001013","article-title":"Brief report: enhanced normalization of CD4\/CD8 ratio with earlier antiretroviral therapy at primary HIV infection","volume":"73","author":"Thornhill","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025052602120295800_ofaf247-B7","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1258\/ijsa.2010.010292","article-title":"Effect of antiretroviral therapy on HIV-1 genetic evolution during acute infection","volume":"22","author":"Chamberland","year":"2011","journal-title":"Int J STD AIDS"},{"key":"2025052602120295800_ofaf247-B8","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1084\/jem.193.2.169","article-title":"Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection","volume":"193","author":"Altfeld","year":"2001","journal-title":"J Exp Med"},{"key":"2025052602120295800_ofaf247-B9","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/QAD.0b013e3283463c07","article-title":"Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection","volume":"25","author":"Gay","year":"2011","journal-title":"AIDS"},{"key":"2025052602120295800_ofaf247-B10","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/QAI.0b013e318285cd33","article-title":"Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation","volume":"62","author":"Vinikoor","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025052602120295800_ofaf247-B11","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12977-018-0458-6","article-title":"Reduction of inflammation and T cell activation after 6 months of cART initiation during acute, but not in early chronic HIV-1 infection","volume":"15","author":"de Paula","year":"2018","journal-title":"Retrovirology"},{"key":"2025052602120295800_ofaf247-B12","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/COH.0000000000000122","article-title":"How does the timing of antiretroviral therapy initiation in acute infection affect HIV reservoirs?","volume":"10","author":"Ananworanich","year":"2015","journal-title":"Curr Opin HIV AIDS"},{"key":"2025052602120295800_ofaf247-B13","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/QAI.0000000000001789","article-title":"Early and highly suppressive antiretroviral therapy are main factors associated with low viral reservoir in European perinatally HIV-infected children","volume":"79","author":"Tagarro","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025052602120295800_ofaf247-B14","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/00126334-200407010-00004","article-title":"Initiation of antiretroviral therapy during recent HIV-1 infection results in lower residual viral reservoirs","volume":"36","author":"Pires","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025052602120295800_ofaf247-B15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3389\/fmicb.2019.00145","article-title":"Reduction of HIV-1 reservoir size and diversity after 1 year of cART among Brazilian individuals starting treatment during early stages of acute infection","volume":"10","author":"Leite","year":"2019","journal-title":"Front Microbiol"},{"key":"2025052602120295800_ofaf247-B16","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1086\/428777","article-title":"Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1","volume":"191","author":"Strain","year":"2005","journal-title":"J Infect Dis"},{"key":"2025052602120295800_ofaf247-B17","doi-asserted-by":"crossref","first-page":"e1006478","DOI":"10.1371\/journal.ppat.1006478","article-title":"Treatment with integrase inhibitor suggests a new interpretation of HIV RNA decay curves that reveals a subset of cells with slow integration","volume":"13","author":"Cardozo","year":"2017","journal-title":"PLoS Pathog"},{"key":"2025052602120295800_ofaf247-B18","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1097\/QAI.0b013e3181fcc0f1","article-title":"Integrase and fusion inhibitors transmitted drug resistance in naive patients with recent diagnosis of HIV-1 infection","volume":"56","author":"Cossarini","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025052602120295800_ofaf247-B19","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/infdis\/jiw165","article-title":"Successful prevention of transmission of integrase resistance in the Swiss HIV cohort study","volume":"214","author":"Scherrer","year":"2016","journal-title":"J Infect Dis"},{"key":"2025052602120295800_ofaf247-B20","doi-asserted-by":"crossref","first-page":"ofz060","DOI":"10.1093\/ofid\/ofz060","article-title":"Prevalence of human immunodeficiency virus-1 integrase strand transfer inhibitor resistance in British Columbia, Canada between 2009 and 2016: a longitudinal analysis","volume":"6","author":"Kamelian","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2025052602120295800_ofaf247-B21","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/QAI.0b013e3181b064b0","article-title":"Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection","volume":"52","author":"Markowitz","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","key":"2025052602120295800_ofaf247-B22"},{"key":"2025052602120295800_ofaf247-B23","doi-asserted-by":"crossref","first-page":"68","DOI":"10.18433\/J39S3T","article-title":"Association of HLA-B*5701 genotypes and abacavir-induced hypersensitivity reaction: a systematic review and meta-analysis","volume":"18","author":"Tangamornsuksan","year":"2015","journal-title":"J Pharm Pharm Sci"},{"key":"2025052602120295800_ofaf247-B24","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1128\/JVI.02383-07","article-title":"Emergence of polyfunctional CD8+ T cells after prolonged suppression of human immunodeficiency virus replication by antiretroviral therapy","volume":"82","author":"Rehr","year":"2008","journal-title":"J Virol"},{"key":"2025052602120295800_ofaf247-B25","doi-asserted-by":"crossref","first-page":"e25484","DOI":"10.1002\/jia2.25484","article-title":"Weight gain among treatment-naive persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada","volume":"23","author":"Bourgi","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"2025052602120295800_ofaf247-B26","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/QAI.0000000000002556","article-title":"Brief report: weight gain following ART initiation in ART-naive people living with HIV in the current treatment era","volume":"86","author":"Ruderman","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025052602120295800_ofaf247-B27","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/cid\/ciz407","article-title":"Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy","volume":"70","author":"Bourgi","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025052602120295800_ofaf247-B28","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1097\/QAD.0000000000001255","article-title":"Fixed-dose combination emtricitabine\/tenofovir\/efavirenz initiated during acute HIV infection; 96-week efficacy and durability","volume":"30","author":"Gay","year":"2016","journal-title":"AIDS"},{"key":"2025052602120295800_ofaf247-B29","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/jac\/dkae391","article-title":"Rapid viral suppression using integrase inhibitors during acute HIV-1 infection","volume":"80","author":"McKellar","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2025052602120295800_ofaf247-B30","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/cyto.a.24707","article-title":"OMIP-087: thirty-two parameter mass cytometry panel to assess human CD4 and CD8 T cell activation, memory subsets, and helper subsets","volume":"103","author":"Sponaugle","year":"2023","journal-title":"Cytometry A"},{"key":"2025052602120295800_ofaf247-B31","doi-asserted-by":"crossref","first-page":"5116","DOI":"10.1073\/pnas.091062498","article-title":"Significance analysis of microarrays applied to the ionizing radiation response","volume":"98","author":"Tusher","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025052602120295800_ofaf247-B32","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.3389\/fimmu.2020.01971","article-title":"Measuring the inducible, replication-competent HIV reservoir using an ultra-sensitive p24 readout, the digital ELISA viral outgrowth assay","volume":"11","author":"Stuelke","year":"2020","journal-title":"Front Immunol"},{"key":"2025052602120295800_ofaf247-B33","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1084\/jem.20030735","article-title":"Interleukin 7 regulates the survival and generation of memory CD4 cells","volume":"198","author":"Kondrack","year":"2003","journal-title":"J Exp Med"},{"key":"2025052602120295800_ofaf247-B34","doi-asserted-by":"crossref","first-page":"E2770","DOI":"10.1073\/pnas.1408792111","article-title":"Automated identification of stratifying signatures in cellular subpopulations","volume":"111","author":"Bruggner","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025052602120295800_ofaf247-B35","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/cid\/ciw076","article-title":"Determinants of a low CD4\/CD8 ratio in HIV-1-infected individuals despite long-term viral suppression","volume":"62","author":"Caby","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2025052602120295800_ofaf247-B36","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1016\/S2352-3018(15)00006-5","article-title":"CD4\/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study","volume":"2","author":"Mussini","year":"2015","journal-title":"Lancet HIV"},{"key":"2025052602120295800_ofaf247-B37","doi-asserted-by":"crossref","first-page":"101268","DOI":"10.1016\/j.xcrm.2023.101268","article-title":"Dominant CD4(+) T cell receptors remain stable throughout antiretroviral therapy-mediated immune restoration in people with HIV","volume":"4","author":"Sponaugle","year":"2023","journal-title":"Cell Rep Med"},{"key":"2025052602120295800_ofaf247-B38","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12865-019-0319-7","article-title":"Foxp3(+)Helios(+) regulatory T cells are associated with monocyte subsets and their PD-1 expression during acute HIV-1 infection","volume":"20","author":"Liu","year":"2019","journal-title":"BMC Immunol"},{"key":"2025052602120295800_ofaf247-B39","doi-asserted-by":"crossref","first-page":"9523","DOI":"10.1073\/pnas.1120248109","article-title":"Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection","volume":"109","author":"Archin","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025052602120295800_ofaf247-B40","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1016\/S2666-5247(21)00010-0","article-title":"Long-term effects of early antiretroviral initiation on HIV reservoir markers: a longitudinal analysis of the MERLIN clinical study","volume":"2","author":"Massanella","year":"2021","journal-title":"Lancet Microbe"},{"key":"2025052602120295800_ofaf247-B41","doi-asserted-by":"crossref","first-page":"e125442","DOI":"10.1172\/jci.insight.125442","article-title":"Mass cytometry identifies distinct CD4+ T cell clusters distinguishing HIV-1-infected patients according to antiretroviral therapy initiation","volume":"4","author":"Bekele","year":"2019","journal-title":"JCI Insight"},{"key":"2025052602120295800_ofaf247-B42","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/infdis\/jiad432","article-title":"Early initiation of antiretroviral therapy preserves the metabolic function of CD4+ T cells in subtype C human immunodeficiency virus 1 infection","volume":"229","author":"Naidoo","year":"2024","journal-title":"J Infect Dis"},{"key":"2025052602120295800_ofaf247-B43","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/jac\/dkv084","article-title":"Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission","volume":"70","author":"Cheret","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2025052602120295800_ofaf247-B44","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/QCO.0000000000000616","article-title":"Weight gain and integrase inhibitors","volume":"33","author":"Eckard","year":"2020","journal-title":"Curr Opin Infect Dis"},{"key":"2025052602120295800_ofaf247-B45","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1056\/NEJMoa1904340","article-title":"Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of HIV-1","volume":"381","author":"Group","year":"2019","journal-title":"N Engl J Med"},{"key":"2025052602120295800_ofaf247-B46","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","article-title":"Dolutegravir plus two different prodrugs of tenofovir to treat HIV","volume":"381","author":"Venter","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaf247\/63002690\/ofaf247.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/5\/ofaf247\/63002690\/ofaf247.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/5\/ofaf247\/63002690\/ofaf247.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T06:12:45Z","timestamp":1748239965000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf247\/8119365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,4,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf247","relation":{},"ISSN":["2328-8957"],"issn-type":[{"type":"electronic","value":"2328-8957"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,4,24]]},"article-number":"ofaf247"}}